PTIX

Aug 20, 2026, 12:30 UTC

Protagenic Therapeutics received written responses from the U.S. Food and Drug Administration to its Type B pre-IND meeting request for PT00114, with the FDA raising no objection to the planned Phase 1 program design, dose-escalation approach, and CMC and nonclinical packages.